|Bid||0.0000 x 0|
|Ask||0.0050 x 0|
|Day's Range||0.0050 - 0.0050|
|52 Week Range||0.0050 - 0.0500|
|Beta (5Y Monthly)||0.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
“Decentralized sales turning social accounts into bank accounts."
LAVAL, Quebec, February 23, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other cough hypersensitivity indications, today reported its financial and operating results for the year ending December 31, 2021.
Also Reviews Summary of 2021's with Focus on Test Marketing of Doc Wylder's